Levels, whose software pairs glucose monitors to its app to give users insights and track their metabolic health, raises a $38M Series A at a $300M valuation
A16z-backed startup Levels has landed $38 million in series A funding for its metabolic health software, the company announced Wednesday. Tweets: @vickerysec Tweets: Chris Vickery / @vickerysec : *endless screaming* Why won't anyone make a device to measure my blood sugar without also uploading it to ‘the cloud’ and handing copies out to every-other-fucking-company in the fucking world? https://twitter.com/...
Context & Ripple Effects
Levels' $12M seed round in late 2020 was an a16z bet on bringing continuous glucose monitoring out of the diabetes clinic and into the consumer wellness market; this $38M Series A at a $300M valuation is that thesis clearing its first institutional checkpoint, with the same lead backer doubling down.
The raise lands in a crowded but well-funded lane: Virta has pulled in successive rounds up to a $133M Series E for clinically supervised metabolic care, Livongo built a connected-device platform for diabetes and hypertension before it, and Q Bio sells continuous monitoring as a high-end subscription — Levels' differentiation is pairing off-the-shelf glucose sensors with consumer insights software rather than owning the device or the clinical pathway.
First-order effects
- Andreessen Horowitz now holds a position across both of Levels' priced rounds, giving the startup roughly $50M of disclosed backing to scale its app-and-sensor pairing beyond early adopters while its valuation steps up from seed to $300M.
Second-order effects
- Virta's clinically anchored model and Levels' consumer model are converging on the same metabolic-health customer, pressuring each to add what the other has — Virta already layers frequent monitoring onto counseling, so Levels' software layer becomes the competitive counterweight.
- The public reaction captured in the article — security researcher Chris Vickery objecting to glucose data being uploaded and shared across companies — signals that data-handling practices will be a battleground for consumer CGM apps, favoring players who can minimize third-party data flows.
Third-order effects
- If the funding pattern across Livongo, Virta, Q Bio, and Levels holds, continuous biometric monitoring is structurally splitting into two distribution models — clinical/employer channels versus direct-to-consumer subscriptions — with sensor makers supplying both and software becoming the margin layer.
- Sustained consumer demand for glucose data outside medical settings will likely force clearer norms or regulation around who may share biometric streams, turning privacy architecture into a durable competitive asset rather than a compliance afterthought.
The trend: Venture capital is steadily moving continuous metabolic monitoring from a clinical diabetes market toward consumer wellness software, with each funding round raising the stakes on who owns the patient's biometric data.